CALCITONIN GENE-RELATED PEPTIDE RECEPTOR (CGRP-R) ANTAGONIST
Aimovig is approved by the Food and Drug Administration (FDA) to prevent migraine in adults. Aimovig is also referred to by its drug name, Erenumab-aooe.
Aimovig is a biologic drug – a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Aimovig is also the first member of a new class of drugs called calcitonin gene-related peptide receptor (CGRP-R) antagonists. Aimovig is believed to work by interfering with CGRP, a substance that dilates blood vessels and contributes to pain signals and inflammation.
How do I take it?
Prescribing information states that Aimovig is administered as a subcutaneous injection once a month.
Aimovig comes in prefilled, single-dose formats as a syringe or an autoinjector.
The FDA-approved label for Aimovig lists common side effects including constipation and injection site reactions.
Because Aimovig is a new drug, its long-term effects are not yet known.
For more details about this treatment, visit:
Aimovig.com – Amgen